Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata : A split-scalp, double-blind, controlled study
(2022) In International Journal of Trichology 14(3). p.91-96- Abstract
Background: The combination of diphenylcyclopropenone (DCP) and anthralin may demonstrate synergistic effects in the treatment of chronic extensive alopecia areata (AA).
Objective: The objective of the study was to compare the efficacy of the combination therapy of topical DCP and topical 0.5% anthralin versus topical DCP alone for the treatment of chronic extensive AA.
Materials and Methods: Ten patients were included in the study. Of these, 1, 2, and 7 patients were diagnosed with alopecia totalis, severe AA (>50% hair loss), and alopecia universalis, respectively. For each patient, one side of the scalp was treated with a DCP solution and 0.5% anthralin for 6 months, while the other side was treated with DCP and a... (More)
Background: The combination of diphenylcyclopropenone (DCP) and anthralin may demonstrate synergistic effects in the treatment of chronic extensive alopecia areata (AA).
Objective: The objective of the study was to compare the efficacy of the combination therapy of topical DCP and topical 0.5% anthralin versus topical DCP alone for the treatment of chronic extensive AA.
Materials and Methods: Ten patients were included in the study. Of these, 1, 2, and 7 patients were diagnosed with alopecia totalis, severe AA (>50% hair loss), and alopecia universalis, respectively. For each patient, one side of the scalp was treated with a DCP solution and 0.5% anthralin for 6 months, while the other side was treated with DCP and a cream base for the same duration. The clinical responses were assessed at baseline and then monthly until the end of the 6-month study period using the Severity of Alopecia Tool score. The side effects were evaluated at each follow-up visit.
Results: The difference in the efficacies of the combination treatment and DCP alone was not statistically significant (
P = 0.59). Regarding the side effects, DCP plus 0.5% anthralin caused significantly more excessive dermatitis than DCP alone (7 patients vs. 2 patients;
P = 0.02). Eight patients reported temporary hyperpigmentation at the combination-treatment site, whereas no hyperpigmentation was reported at the DCP-alone site of any patient (
P < 0.001).
Conclusions: The combination of DCP and 0.5% anthralin was not superior to DCP alone for the treatment of chronic extensive AA. An increase in side effects - excessive dermatitis and hyperpigmentation - was observed in the combination-treatment group.
(Less)
- author
- Thuangtong, Rattapon ; Suvansuthi, Saroj ; Maneeprasopchoke, Pitchaya ; Sukakul, Thanisorn LU ; Techakajornkeart, Rattiya ; Chaweekulrat, Pichanee ; Wongdama, Supisara and Triwongwaranat, Daranporn
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- in
- International Journal of Trichology
- volume
- 14
- issue
- 3
- pages
- 6 pages
- publisher
- Wolters Kluwer
- external identifiers
-
- scopus:85131649215
- pmid:35755959
- ISSN
- 0974-7753
- DOI
- 10.4103/ijt.ijt_72_21
- language
- English
- LU publication?
- no
- additional info
- Copyright: © 2022 International Journal of Trichology.
- id
- a9cda3fb-3e87-4b21-9017-61d090358f85
- date added to LUP
- 2022-09-06 10:10:23
- date last changed
- 2024-04-18 13:43:55
@article{a9cda3fb-3e87-4b21-9017-61d090358f85, abstract = {{<p>Background: The combination of diphenylcyclopropenone (DCP) and anthralin may demonstrate synergistic effects in the treatment of chronic extensive alopecia areata (AA).</p><p>Objective: The objective of the study was to compare the efficacy of the combination therapy of topical DCP and topical 0.5% anthralin versus topical DCP alone for the treatment of chronic extensive AA.</p><p>Materials and Methods: Ten patients were included in the study. Of these, 1, 2, and 7 patients were diagnosed with alopecia totalis, severe AA (>50% hair loss), and alopecia universalis, respectively. For each patient, one side of the scalp was treated with a DCP solution and 0.5% anthralin for 6 months, while the other side was treated with DCP and a cream base for the same duration. The clinical responses were assessed at baseline and then monthly until the end of the 6-month study period using the Severity of Alopecia Tool score. The side effects were evaluated at each follow-up visit.</p><p>Results: The difference in the efficacies of the combination treatment and DCP alone was not statistically significant (<br> P = 0.59). Regarding the side effects, DCP plus 0.5% anthralin caused significantly more excessive dermatitis than DCP alone (7 patients vs. 2 patients; <br> P = 0.02). Eight patients reported temporary hyperpigmentation at the combination-treatment site, whereas no hyperpigmentation was reported at the DCP-alone site of any patient (<br> P < 0.001).<br> </p><p>Conclusions: The combination of DCP and 0.5% anthralin was not superior to DCP alone for the treatment of chronic extensive AA. An increase in side effects - excessive dermatitis and hyperpigmentation - was observed in the combination-treatment group.</p>}}, author = {{Thuangtong, Rattapon and Suvansuthi, Saroj and Maneeprasopchoke, Pitchaya and Sukakul, Thanisorn and Techakajornkeart, Rattiya and Chaweekulrat, Pichanee and Wongdama, Supisara and Triwongwaranat, Daranporn}}, issn = {{0974-7753}}, language = {{eng}}, number = {{3}}, pages = {{91--96}}, publisher = {{Wolters Kluwer}}, series = {{International Journal of Trichology}}, title = {{Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata : A split-scalp, double-blind, controlled study}}, url = {{http://dx.doi.org/10.4103/ijt.ijt_72_21}}, doi = {{10.4103/ijt.ijt_72_21}}, volume = {{14}}, year = {{2022}}, }